Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Free Cash Flow: 2013-2025

Historic Free Cash Flow for KalVista Pharmaceuticals (KALV) over the last 13 years, with Apr 2025 value amounting to -$153.4 million.

  • KalVista Pharmaceuticals' Free Cash Flow fell 166.88% to -$40.6 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$135.8 million, marking a year-over-year decrease of 51.54%. This contributed to the annual value of -$153.4 million for FY2025, which is 71.15% down from last year.
  • KalVista Pharmaceuticals' Free Cash Flow amounted to -$153.4 million in FY2025, which was down 71.15% from -$89.6 million recorded in FY2024.
  • In the past 5 years, KalVista Pharmaceuticals' Free Cash Flow registered a high of -$30.3 million during FY2021, and its lowest value of -$153.4 million during FY2025.
  • Its 3-year average for Free Cash Flow is -$106.5 million, with a median of -$89.6 million in 2024.
  • As far as peak fluctuations go, KalVista Pharmaceuticals' Free Cash Flow skyrocketed by 32.82% in 2021, and later plummeted by 161.35% in 2022.
  • Over the past 5 years, KalVista Pharmaceuticals' Free Cash Flow (Yearly) stood at -$30.3 million in 2021, then tumbled by 161.35% to -$79.1 million in 2022, then rose by 3.30% to -$76.5 million in 2023, then fell by 17.23% to -$89.6 million in 2024, then plummeted by 71.15% to -$153.4 million in 2025.